THOUSAND OAKS, Calif., April 22, 2014 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced financial results for the first quarter of 2014. Key results include:
•Total revenues increased 7 percent to $4,521 million, with 5 percent product sales growth driven by Kyprolis® (carfilzomib), XGEVA® (denosumab), Prolia® (denosumab) and Neulasta® (pegfilgrastim).
Help employers find you! Check out all the jobs and post your resume.
